Open Access
CC BY 4.0 · Planta Med 2024; 90(09): 664-674
DOI: 10.1055/a-2307-8183
Biological and Pharmacological Activity
Reviews

The Clinical Translation of α-humulene – A Scoping Review

1   Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK
,
Martha Nicholas*
1   Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK
,
Manaswini Pillai*
1   Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK
,
Simon Erridge
1   Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK
2   Curaleaf Clinic, London, UK
,
Mikael H. Sodergren
1   Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, UK
3   Curaleaf International, London, UK
› Author Affiliations
Preview

Abstract

α-humulene, a sesquiterpene found in essential oils of various plant species, has garnered interest due to its potential therapeutic applications. This scoping review aims to consolidate α-humuleneʼs evidence base, informing clinical translation, and guiding future research directions. A scoping review was conducted of EMBASE, MEDLINE, and PubMed databases up to 14th July 2023. All studies describing original research on α-humulene extraction, as well as pre-clinical and clinical research, were included for review. Three hundred and forty articles were analysed. α-humulene yields ranged from negligible to 60.90% across plant species. In vitro experiments demonstrated cytotoxicity against adenocarcinomas (such as colorectal, pulmonary, breast, prostatic, lung, and ovarian), with varying responses in other cell models. Mechanistic insights revealed its involvement in mitochondrial dysfunction, diminished intracellular glutathione levels, and the induction of oxidative stress. In rodent studies, oral administration of α-humulene at 50 mg/kg reduced inflammation markers in paw oedema and ovalbumin-induced airway inflammation. Intraperitoneal administration of α-humulene (50 – 200 mg/kg) exhibited cannabimimetic properties through cannabinoid 1 and adenosine A2a receptors. α-humulene also exhibited a multitude of properties with potential scope for therapeutic utilisation. However, there is a paucity of studies that have successfully translated this research into clinical populations with the associated disease. Potential barriers to clinical translation were identified, including yield variability, limited isolation studies, and challenges associated with terpene bioavailability. Consequently, rigorous pharmacokinetic studies and further mechanistic investigations are warranted to effectively uncover the potential of α-humulene.

* Nishaanth Dalavaye, Martha Nicholas, and Manaswini Pillai are to be considered as joint first authors


Supporting Information



Publication History

Received: 30 September 2023

Accepted after revision: 16 April 2024

Accepted Manuscript online:
16 April 2024

Article published online:
08 May 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany